MCID: DNG005
MIFTS: 62

Dengue Virus

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 58
Dengue Fever, Protection Against 58 13 6
Dengue Virus, Susceptibility to 58 30 41
Dengue Fever 60 74
Dengue Virus Infection 60
Df 60

Characteristics:

Orphanet epidemiological data:

60
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


Summaries for Dengue Virus

OMIM : 58 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to japanese encephalitis and west nile virus, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are fever and headache

CDC : 3 Dengue

Wikipedia : 77 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 japanese encephalitis 30.9 CD209 DDX58
2 west nile virus 30.8 CD209 DDX58 EXOC1 IFIH1 IFITM1 IFITM2
3 chikungunya 30.8 DDX58 OAS3 RSAD2
4 encephalitis 30.7 CD209 DDX58 RPSA RSAD2
5 noonan syndrome 3 30.5 DDX58 NRBP1 RSAD2 STAT2
6 hepatitis 30.3 CLDN1 DDX58 HAVCR1
7 rift valley fever 30.1 CD209 IFITM3
8 tick-borne encephalitis 29.9 CD209 OAS3
9 noonan syndrome 2 29.9 DDX58 STAT2
10 herpes simplex 29.7 CD209 DDX58 IFIH1
11 measles 29.6 CD209 DDX58 IFIH1 STAT2
12 influenza 29.4 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 RSAD2
13 hepatitis c virus 29.1 CLDN1 DDX58 IFIH1 IFITM1 RSAD2
14 dengue disease 12.3
15 dengue shock syndrome 11.7
16 asymptomatic dengue 11.7
17 dengue hemorrhagic fever 11.6
18 kyasanur forest disease 11.2
19 noonan syndrome 5 10.7
20 yellow fever 10.4
21 guillain-barre syndrome 10.4
22 thrombocytopenia 10.3
23 zika fever 10.3
24 zika virus infection 10.3
25 marburg hemorrhagic fever 10.3 CD209 STAT2
26 cytokine deficiency 10.2
27 singleton-merten syndrome 10.2 DDX58 IFIH1
28 kawasaki disease 10.2
29 cardiac tamponade 10.1
30 hepatitis a 10.1
31 appendicitis 10.1
32 malaria 10.1
33 viral infectious disease 10.1 CD209 DDX58 IFIH1
34 diabetic foot ulcers 10.1
35 systemic lupus erythematosus 10.1
36 neutropenia 10.1
37 thrombosis 10.1
38 acute kidney tubular necrosis 10.1
39 acute pancreatitis 10.1
40 pancreatitis 10.1
41 acute disseminated encephalomyelitis 10.1
42 broken heart syndrome 10.1
43 leukemia 10.1
44 st. louis encephalitis 10.1
45 myelitis 10.1
46 vaccinia 10.1
47 transverse myelitis 10.1
48 microphthalmia with limb anomalies 10.0 OAS3 STAT2
49 blood group, colton system 10.0
50 ataxia and polyneuropathy, adult-onset 10.0

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Human phenotypes related to Dengue Virus:

60 33 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
2 headache 60 33 hallmark (90%) Very frequent (99-80%) HP:0002315
3 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
4 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
5 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
6 skin rash 60 33 frequent (33%) Frequent (79-30%) HP:0000988
7 nausea and vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002017
8 hypotension 60 33 occasional (7.5%) Occasional (29-5%) HP:0002615
9 hepatomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0002240
10 ascites 60 33 occasional (7.5%) Occasional (29-5%) HP:0001541
11 thrombocytopenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001873
12 gastrointestinal hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0002239
13 diarrhea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002014
14 epistaxis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000421
15 bruising susceptibility 60 33 occasional (7.5%) Occasional (29-5%) HP:0000978
16 gingival bleeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0000225
17 petechiae 60 33 occasional (7.5%) Occasional (29-5%) HP:0000967
18 lethargy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001254
19 cerebral hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0001342
20 leukopenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001882
21 hypoproteinemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003075
22 cardiorespiratory arrest 60 33 occasional (7.5%) Occasional (29-5%) HP:0006543

Clinical features from OMIM:

614371

UMLS symptoms related to Dengue Virus:


fever, pruritus

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Histamine Phosphate Phase 4 51-74-1 65513
4 Anti-Allergic Agents Phase 4
5 Neurotransmitter Agents Phase 4
6 Histamine H1 Antagonists Phase 4
7 Antipruritics Phase 4
8 Dermatologic Agents Phase 4
9 Histamine Antagonists Phase 4
10 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
11 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
13 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
14
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
15 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
16 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
17 Antibodies, Monoclonal Phase 2,Phase 1
18
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
19
Aluminum sulfate Approved Phase 1 10043-01-3
20
Varespladib methyl Investigational Phase 1 172733-08-3
21 Gastrointestinal Agents Phase 1
22 Antacids Phase 1
23 Anti-Ulcer Agents Phase 1
24 Adjuvants, Immunologic Phase 1
25
Mebendazole Approved, Vet_approved Not Applicable 31431-39-7 4030
26
Albendazole Approved, Vet_approved Not Applicable 54965-21-8 2082
27
Ivermectin Approved, Investigational, Vet_approved Not Applicable 70288-86-7 6474909
28
Caffeine Approved Not Applicable 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Active, not recruiting NCT02555072 Phase 4
3 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Completed NCT02979535 Phase 3
4 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
5 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
6 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
7 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
8 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
9 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Completed NCT03341637 Phase 3
10 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
11 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
12 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
14 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
15 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine Active, not recruiting NCT03525119 Phase 3
16 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
17 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
18 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
19 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
20 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
21 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
22 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
23 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
24 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
25 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
26 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
27 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
28 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
29 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
30 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
31 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
32 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
33 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults Recruiting NCT02421367 Phase 1, Phase 2
34 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults Recruiting NCT03746015 Phase 2
35 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
36 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
37 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
38 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
39 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
40 A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan Active, not recruiting NCT03485144 Phase 2
41 Safety and Immunogenicity of Takeda's TDV in Healthy Children Active, not recruiting NCT02948829 Phase 2
42 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
43 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
44 IC14 in Adult Patients With Dengue Fever Withdrawn NCT03875560 Phase 2 Placebo
45 Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Completed NCT01073306 Phase 1
46 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01436422 Phase 1
47 Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01072786 Phase 1
48 Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Completed NCT01931176 Phase 1
49 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine Completed NCT02684383 Phase 1
50 Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Completed NCT01084291 Phase 1

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 30 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

42
Testes, T Cells, Liver, Endothelial, Skin, Monocytes, Heart

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 4631)
# Title Authors Year
1
Dengue fever with chikungunya concurrent infection. ( 30692836 )
2019
2
Simultaneous detection of Dengue virus, Chikungunya virus, Zika virus, Yellow fever virus and West Nile virus. ( 30930286 )
2019
3
Cross-Protection of Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil. ( 31075077 )
2019
4
Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever. ( 30868055 )
2019
5
Evaluation of biochemical and haematological changes in dengue fever and dengue hemorrhagic fever in Sri Lankan children: a prospective follow up study. ( 30935373 )
2019
6
Pathogen blocking in Wolbachia-infected Aedes aegypti is not affected by Zika and dengue virus co-infection. ( 31107912 )
2019
7
Seroprevalence for dengue virus in a hyperendemic area and associated socioeconomic and demographic factors using a cross-sectional design and a geostatistical approach, state of São Paulo, Brazil. ( 31109295 )
2019
8
Mast Cell Stabilizing Effect of A Geranyl Acetophenone in Dengue Virus Infection using In Vitro Model of DENV3-Induced RBL-2H3 Cells. ( 31110077 )
2019
9
Seroprevalence of Dengue Virus and Rickettsial Infections in Cambodian Children. ( 30675849 )
2019
10
Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. ( 30677305 )
2019
11
Adaptive immune responses to primary and secondary dengue virus infections. ( 30679808 )
2019
12
Dynamics and binding interactions of peptide inhibitors of dengue virus entry. ( 30680580 )
2019
13
Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned. ( 30682026 )
2019
14
Protein refolding based on high hydrostatic pressure and alkaline pH: Application on a recombinant dengue virus NS1 protein. ( 30682103 )
2019
15
Genotypic persistence of dengue virus in the Philippines. ( 30682551 )
2019
16
Infectivity of Dengue Virus Serotypes 1 and 2 Is Correlated with E-Protein Intrinsic Dynamics but Not to Envelope Conformations. ( 30686666 )
2019
17
Role of non-electrostatic forces in antimicrobial potency of a dengue-virus derived fusion peptide VG16KRKP: Mechanistic insight into the interfacial peptide-lipid interactions. ( 30689979 )
2019
18
Dengue virus serotypes and genotypic characterization from northeast India. ( 30698841 )
2019
19
Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi, Kenya. ( 30701251 )
2019
20
Correction: Small-Molecule Inhibitors of Dengue-Virus Entry. ( 30703168 )
2019
21
Mutagenesis of the dengue virus NS4A protein reveals a novel cytosolic N-terminal domain responsible for virus-induced cytopathic effects and intramolecular interactions within the N-terminus of NS4A. ( 30707666 )
2019
22
Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. ( 30723263 )
2019
23
Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy. ( 30737148 )
2019
24
Acceptability of Aedes aegypti blood feeding on dengue virus-infected human volunteers for vector competence studies in Iquitos, Peru. ( 30742621 )
2019
25
Effect of freeze-dried Carica papaya leaf juice on inflammatory cytokines production during dengue virus infection in AG129 mice. ( 30744623 )
2019
26
Dengue virus transmission from live donor liver graft: A comment. ( 30748081 )
2019
27
Feasibility of feeding Aedes aegypti mosquitoes on dengue virus-infected human volunteers for vector competence studies in Iquitos, Peru. ( 30753180 )
2019
28
Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4+ T Cells to the Dengue Virus Envelope Protein Domain III. ( 30761131 )
2019
29
Significance of Autophagy in Dengue Virus Infection: A Brief Review. ( 30761986 )
2019
30
Dengue virus transmission from live donor liver graft: Comments and clarifications. ( 30768850 )
2019
31
A new immunoassay of hybrid nanomater conjugated to aptamers for the detection of dengue virus. ( 30771965 )
2019
32
Natural vertical infection by dengue virus serotype 4, Zika virus and Mayaro virus in Aedes (Stegomyia) aegypti and Aedes (Stegomyia) albopictus. ( 30776139 )
2019
33
Protein Disulfide Isomerase Inhibitor Suppresses Viral Replication and Production during Antibody-Dependent Enhancement of Dengue Virus Infection in Human Monocytic Cells. ( 30781856 )
2019
34
Invasion of a murine in vitro blood-brain barrier co-culture model by dengue virus serotypes 1 to 4. ( 30783772 )
2019
35
Entomological and virological surveillance for dengue virus in churches in Merida, Mexico. ( 30785563 )
2019
36
Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice. ( 30790202 )
2019
37
Risk Factors Associated with Dengue Virus Infection in Guangdong Province: A Community-Based Case-Control Study. ( 30791547 )
2019
38
Co-circulation of dengue virus serotypes in Central India: Evidence of prolonged viremia in DENV-2. ( 30798036 )
2019
39
Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity. ( 30804377 )
2019
40
Mutations in the dimer interfaces of the dengue virus capsid protein affect structural stability and impair RNA-capsid interaction. ( 30808916 )
2019
41
Efficacy of geraniin on dengue virus type-2 infected BALB/c mice. ( 30813954 )
2019
42
In vitro antiviral activity of spirotetronate compounds against dengue virus serotype 2. ( 30814437 )
2019
43
Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. ( 30820456 )
2019
44
Epidemiological and clinical characteristics of Dengue virus outbreaks in two regions of China, 2014 - 2015. ( 30835769 )
2019
45
Mosquito cells persistently infected with dengue virus produce viral particles with host-dependent replication. ( 30844508 )
2019
46
Structural perspectives of antibody-dependent enhancement of infection of dengue virus. ( 30844538 )
2019
47
Tracking dengue virus type 1 genetic diversity during lineage replacement in an hyperendemic area in Colombia. ( 30845200 )
2019
48
Inhibition of N-myristoyltransferase1 affects dengue virus replication. ( 30848105 )
2019
49
Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil. ( 30856223 )
2019
50
First dengue virus seroprevalence study on Madeira Island after the 2012 outbreak indicates unreported dengue circulation. ( 30867031 )
2019

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CD209 CD209, -336A-G single nucleotide variant protective,risk factor

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 CD209 CLDN1 CLEC5A DDX58 EXOC1 IFITM1

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.97 CD209 CLEC5A DDX58 IFIH1 IFITM1 IFITM2
2 viral entry into host cell GO:0046718 9.85 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA
3 negative regulation of viral genome replication GO:0045071 9.8 IFITM1 IFITM2 IFITM3 OAS3 RSAD2
4 cellular response to interferon-gamma GO:0071346 9.78 CLDN1 LGALS9 MRC1
5 type I interferon signaling pathway GO:0060337 9.73 IFITM1 IFITM2 IFITM3 OAS3 RSAD2 STAT2
6 positive regulation of interleukin-6 secretion GO:2000778 9.71 DDX58 IFIH1 LGALS9
7 response to interferon-gamma GO:0034341 9.7 IFITM1 IFITM2 IFITM3
8 response to virus GO:0009615 9.7 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 OAS3
9 negative regulation of viral entry into host cell GO:0046597 9.69 IFITM1 IFITM2 IFITM3
10 positive regulation of tumor necrosis factor secretion GO:1904469 9.67 DDX58 IFIH1 LGALS9
11 response to interferon-alpha GO:0035455 9.63 IFITM1 IFITM2 IFITM3
12 negative regulation of type I interferon production GO:0032480 9.62 DDX58 IFIH1
13 positive regulation of interferon-beta production GO:0032728 9.62 DDX58 IFIH1
14 cellular response to exogenous dsRNA GO:0071360 9.61 DDX58 IFIH1
15 response to interferon-beta GO:0035456 9.61 IFITM1 IFITM2 IFITM3
16 defense response to virus GO:0051607 9.61 DDX58 EXOC1 IFIH1 IFITM1 IFITM2 IFITM3
17 positive regulation of interferon-alpha production GO:0032727 9.6 DDX58 IFIH1
18 positive regulation of interferon-alpha secretion GO:1902741 9.59 DDX58 IFIH1
19 positive regulation of response to cytokine stimulus GO:0060760 9.58 DDX58 IFIH1
20 detection of virus GO:0009597 9.58 DDX58 IFIH1
21 positive regulation of interferon-beta secretion GO:0035549 9.57 DDX58 IFIH1
22 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.56 DDX58 IFIH1
23 regulation of type III interferon production GO:0034344 9.55 DDX58 IFIH1
24 viral process GO:0016032 9.36 CD209 CLDN1 CLEC5A DDX58 EXOC1 HAVCR1
25 immune system process GO:0002376 10.02 CD209 CLEC5A DDX58 IFIH1 IFITM1 OAS3

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 DDX58 IFIH1 OAS3
2 mannose binding GO:0005537 9.26 CD209 MRC1
3 carbohydrate binding GO:0030246 9.26 CD209 CLEC5A LGALS9 MRC1
4 virus receptor activity GO:0001618 9.1 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....